--India-based Jubilant Life Sciences Ltd. has reached a non-exclusive licensing agreement to sell Gilead Sciences Inc.'s Covid-19 treatment remdesivir in 127 countries, Reuters reported Tuesday.

--Jubliant will also have manufacturing rights in many countries, the report said.

--Last week, Gilead said it would work with other companies to manufacture and sell remdesivir outside of the U.S. and was negotiating with drugmakers in India and Pakistan to grant long-term licenses to sell generic versions.

Full story: https://www.reuters.com/article/us-health-coronavirus-gilead-sciences/indias-jubilant-signs-licensing-deal-for-gileads-potential-covid-19-drug-idUSKBN22O2HJ

Write to Josh Beckerman at josh.beckerman@wsj.com

(END) Dow Jones Newswires

May 12, 2020 14:57 ET (18:57 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Gilead Sciences Charts.
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Gilead Sciences Charts.